Technology

TAVO

To date, OncoSec’s immunotherapy platform, Intratumoral IL-12, focuses on the delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The treatment is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, which in turn, enables the immune system to target and attack tumors throughout the body.

OncoSec is currently investigating TAVO for treatment of metastatic melanoma and triple negative breast cancer. As the company continues to evaluate TAVO in these current indications, OncoSec is developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.

 

HOW IT WORKS

1
1 1
1. Cancer is identified in the body.
2
2 2
2. DNA-based interleukin-12 (IL-12), a naturally occurring protein, is injected directly into the tumor.
3
3 3
3. The applicator supplies a sequence of short-duration electrical pulses through a series of needles.
4
4 4
4. Electrical pulses result in increased permeability of the cell membrane, allowing DNA-based IL-12 to enter.
5
5 5
5. DNA-based IL-12 is expressed in the local tumor microenvironment.
6
6 6
6. IL-12 drives local inflammatory response in the tumor.
7
7 7
7. Immune cells are educated to recognize the patient’s cancer.
8
8 8
8. Educated immune cells identify and attack tumors throughout the body.
1. Cancer is identified in the body.

Positive Results

Data from our multi-center Phase II monotherapy trial of TAVO (OMS-100) demonstrated encouraging single-agent activity with an abscopal effect in 29 patients with metastatic melanoma.

31%
Best Overall Response
14%
Complete Response
48%
Disease Control Rate
50%
Patients Showing Complete Regression in at Least One Untreated Lesion